GLOW combines the BPC-157 and TB-500 repair pair with GHK-Cu, adding skin and hair support to recovery in a single protocol.
This page covers what it is and does, where the evidence stands, our view on using it, and why copper monitoring matters. It also covers why — as with any injected peptide — the source matters as much as the molecule.
Reviewed by Dr. David Oliak, board-certified surgeon
Updated August 2026
GLOW is an injectable peptide blend that combines three peptides: BPC-157, TB-500, and GHK-Cu. The first two are the repair pair used in Wolverine.
BPC-157 is a peptide based on a protein found in gastric juice and studied since the 1990s for tissue repair. TB-500 is the active fragment of Thymosin Beta-4, studied for the migration of repair cells to injured tissue.
GHK-Cu is the third component: a copper-binding peptide the body makes naturally and loses with age, studied for skin quality, hair, and tissue repair. It is what distinguishes GLOW from Wolverine, and it is why GLOW also delivers copper. (See the dedicated Wolverine and GHK-Cu pages for detail on each.)
GLOW is used to support recovery and repair together with skin and hair quality. The reason to combine these three peptides, rather than use the repair pair alone, is to address both goals at once.
The aim is faster, more complete repair alongside better skin quality and support for thinning hair, for someone who wants both rather than either on its own.
In studies, its components have been associated with tissue repair in muscle, tendon, ligament, and skin. They have been associated with reduced inflammation, and with collagen production and skin quality. These are the reported and studied applications; they are not established, FDA-approved indications.
Benefit cluster: recovery & repair · skin quality · hair support · inflammation
GLOW acts across complementary repair pathways. In animal and laboratory studies, BPC-157 has been associated with new blood-vessel formation, tissue regeneration, and reduced inflammation.
TB-500 has been associated with the migration of repair cells and reduced scarring. GHK-Cu, a copper-binding peptide, has been associated with collagen and skin-matrix production, follicle support, and tissue repair.
This picture is drawn largely from preclinical and skin research and has not been established for this blend in human clinical trials.
GLOW's three peptides sit at different points on the evidence scale.
The pattern is consistent across all three: encouraging laboratory and animal work and substantial real-world use, with human trial evidence still limited. In our own practice, GLOW is a popular and well-liked protocol — patients report the recovery benefits of the BPC-157/TB-500 pair together with the skin and hair benefits of GHK-Cu.
Our verdict: GLOW is a sensible combination when the goal is both recovery and skin and hair, rather than recovery alone. It pairs the BPC-157/TB-500 repair peptides with GHK-Cu, a naturally occurring peptide that most patients tolerate well and like.
We find the repair peptides effective for healing and recovery in many, if not most, patients. In our practice it is one of our more popular and well-received protocols.
The evidence is largely preclinical and anecdotal rather than from human trials, so it is promising rather than proven. Because GLOW contains GHK-Cu, it delivers copper: we use it in cycles, monitor copper in longer-term use, and prescribe it from an accountable source.
We choose it as one targeted tool, matched to a defined goal within a considered plan. Where the goal is purely musculoskeletal repair, Wolverine, the same pair without the copper, is often the simpler choice.
— Dr. David Oliak, board-certified physician and surgeon
Because GLOW contains GHK-Cu, it delivers copper, and copper requires attention. The body normally regulates copper absorption in the gut; an injection bypasses that control.
For this reason, GLOW is used in cycles rather than continuously, and longer-term use is monitored with periodic blood testing of copper and ceruloplasmin. It is not appropriate for patients with disorders of copper metabolism, such as Wilson's disease. This is one reason GLOW specifically calls for physician supervision rather than self-administration.
With any injected peptide, the source is a safety issue, not a detail. With GLOW, which also delivers copper, so is the monitoring. We prescribe GLOW compounded for human use by a licensed pharmacy, on a prescription, and supervise its use, including periodic copper testing.
Most peptides sold online are labeled "research use only" — not for human use — and are produced without a regulatory framework to confirm their contents, purity, or sterility.
Reported side effects of GLOW are generally mild and most commonly involve local irritation at the injection site. Human data for this blend is limited, so the long-term safety profile is not fully established. GLOW is not an FDA-approved medication.
Peptide therapy is not appropriate for everyone; your provider will review your history, medications, and goals before prescribing. Why "research use only" peptides are a problem →
Let's begin
Whether GLOW fits your goals, at what dose and cycle, is decided in a consultation. It is set within a plan built around what you are trying to achieve — GLOW for a combined recovery-and-skin goal, or as one part of a broader plan when your goals call for it.
Book a peptide consult for a targeted goal, or start with a comprehensive evaluation when you want the fuller picture first. For current pricing, see our peptide pricing page. To speak with us first, call 714-671-2005.
Wolverine (BPC-157 / TB-500) — the repair pair without GHK-Cu
GHK-Cu — the copper-binding component, on its own
Hair restoration: the science by compound and delivery route
Why "research use only" peptides are a problem